Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2021.657711 http://scihub22266oqcxt.onion/10.3389/fimmu.2021.657711 33777055!7994748!33777055     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2021 ; 12 (ä): 657711 Nephropedia Template TP {{tp|p=33777055|t=2021. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results |pdf=|usr=}}{{33777055}} gab.com Text Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33777055 #FOAvip Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a T(H)1 response and no evidence of vaccine-enhanced disease have been reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited. Twit Text FOAVip Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33777055 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33777055 #FOAvip English Wikipedia <ref>{{Cite pmid|33777055}}</ref> Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results #MMPMID33777055 Lombardi A; Bozzi G; Ungaro R; Villa S; Castelli V; Mangioni D; Muscatello A; Gori A; Bandera A Front Immunol 2021[]; 12 (ä): 657711 PMID33777055show ga Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a T(H)1 response and no evidence of vaccine-enhanced disease have been reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited. |*Immunization[MESH] |*Immunogenicity, Vaccine[MESH] |2019-nCoV Vaccine mRNA-1273[MESH] |Animals[MESH] |Antibodies, Neutralizing/blood[MESH] |Antibodies, Viral/blood[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/adverse effects/*therapeutic use[MESH] |COVID-19/blood/immunology/*prevention & control/virology[MESH] |Diffusion of Innovation[MESH] |Host-Pathogen Interactions[MESH] |Humans[MESH] |SARS-CoV-2/genetics/*immunology[MESH] |Treatment Outcome[MESH] |Vaccines, Synthetic/adverse effects/*therapeutic use[MESH]Mini Review Immunological Consequences of Immunization With COVID-19 m(epmc).pdf DeepDyve Pubget Overpricing